secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066939
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics Q1 net loss $96.8M; cash $1.3B; paltusotine PDUFA Sept 25, 2025
-------------------------------------------------------------------------

- Net loss of $96.8M for Q1 2025 vs. $66.9M in Q1 2024, driven by higher R&D and SG&A costs.
- Revenue $0.4M, down from $0.6M; primarily from Sanwa Kagaku licensing agreement.
- Cash, equivalents, and investments $1.3B, expected to fund operations into 2029.
- Paltusotine NDA under FDA review with PDUFA target action date Sept 25, 2025.
- Phase 3 CALM-CAH study of atumelnant in CAH to begin H2 2025; R&D Day June 26.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025066939/0000950170-25-066939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025066939/crnx-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer